SMS Pharmaceuticals logo

SMS Pharmaceuticals

SMSPHARMA NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹4,145 Cr
Volatility
High Risk
P/E Ratio
42.4
EBITDA
₹171 Cr
Return on Equity
10.54%
Debt to Equity
0.46
Book Value
₹83.91
EPS
₹6.73
52W High
₹447.8
52W Low
₹242.25

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

3
  • Stock is trading at 5.52 times its book value
  • Company has a low return on equity of 12.3% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
12.4% lower than 3Y
Net Income Growth
34.58% lower than 3Y
Cash Flow Change
63.03% lower than 3Y
ROE
14.94% higher than 3Y
ROCE
5.02% lower than 3Y
EBITDA Margin (Avg.)
3.91% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

SMS Pharmaceuticals Ltd is a mid-cap API manufacturer with a market cap of ₹3,944 Cr trading at a PE of 38.7x. The company has delivered strong recent profit growth (48% TTM, 155% 3-year CAGR) on improving operating margins (OPM expanding from 16.3% in FY24 to 19.1% in FY26), though its 3-year average ROE of 12% remains modest relative to its 5.02x price-to-book valuation.

Bull Case 7
  • TTM profit growth of 48% significantly outpaces sales growth of 13%, indicating improving profitability and operating leverage
  • 3-year compounded profit CAGR of 155% reflects a dramatic earnings recovery from the FY23 trough (net profit of just ₹3.88 Cr in FY23 to ₹102 Cr in FY26)
  • Revenue has grown from ₹709 Cr in FY24 to ₹887 Cr in FY26, a healthy 3-year sales CAGR of 19%
  • Operating profit margin expanded from 10.3% in FY23 to 19.1% in FY26, demonstrating sustained margin improvement
  • Stock has delivered a 1-year return of 73% and a 3-year CAGR of 65%, reflecting strong market re-rating
  • Interest costs declined from ₹23.46 Cr in FY24 to ₹18.54 Cr in FY25 before rising to ₹23.08 Cr in FY26, showing the company managed to reduce finance costs during its recovery phase
  • Last year ROE improved to 14% versus the 3-year average of 12% and the 5-year average of 10%, showing an upward trajectory in capital efficiency
Bear Case 8
  • PE of 38.7x is elevated for a company with a 10-year profit CAGR of only 10%, implying significant future growth is already priced in
  • Price-to-book of 5.02x is high relative to 3-year average ROE of just 12.3%, suggesting the stock may not justify its valuation on return metrics alone
  • 10-year sales CAGR of only 4% indicates historically slow top-line growth, raising questions about sustainability of recent acceleration
  • Company might be capitalizing interest costs, which could flatter reported profits and understate true finance charges
  • Dividend yield of just 0.09% (payout ratio ~3.7% in FY26) offers negligible income return to shareholders
  • 5-year compounded profit CAGR of only 10% when viewed over a longer horizon tempers the recent surge narrative
  • Interest costs rose 24% YoY from ₹18.54 Cr in FY25 to ₹23.08 Cr in FY26, suggesting rising debt or working capital needs even as the business scales
  • 5-year stock CAGR of 19% versus the 3-year CAGR of 65% highlights that much of the re-rating is very recent and may not sustain

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Neutral 1
  • No new promoter share pledges Jun 15

    SMS Pharmaceuticals confirmed no new share encumbrances by promoters in FY26. Existing pledges for Mrs. Hima Bindu Potluri and group entities remain unchanged.

TL;DR: Limited news flow for SMS Pharmaceuticals with only a routine disclosure confirming no change in promoter pledge status. No material positives or negatives emerged in the period. The lack of newsflow makes it difficult to assess directional momentum; investors should watch for upcoming quarterly results for clearer signals.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
135
167
161
246
164
197
173
248
196
242
210
238
207
Expenses
109
139
132
212
131
165
140
207
157
194
167
198
166
Operating Profit
26
28
29
34
34
31
33
41
39
48
44
40
41
OPM %
19%
17%
18%
14%
20%
16%
19%
16%
20%
20%
21%
17%
20%
Other Income
1
1
1
2
1
1
2
1
1
1
4
3
2
Interest
6
6
6
6
5
5
4
5
6
6
6
5
6
Depreciation
8
8
8
8
8
9
9
9
10
10
10
10
10
PBT
13
15
17
22
22
20
22
29
24
34
31
27
27
Tax %
31%
21%
26%
26%
25%
29%
24%
30%
23%
26%
26%
23%
26%
Net Profit
9
12
11
17
16
14
18
20
20
25
23
33
21
EPS in Rs
1.1
1.38
1.36
2.04
1.95
1.66
2.15
2.29
2.31
2.7
2.51
3.49
2.23
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
193
611
438
463
465
412
563
520
522
709
783
887
898
Expenses
145
522
363
369
375
332
442
405
467
593
644
716
725
Operating Profit
47
89
75
93
90
80
121
115
55
117
139
171
173
OPM %
25%
15%
17%
20%
19%
19%
22%
22%
10%
16%
18%
19%
19%
Other Income
5
4
1
2
3
5
3
5
5
4
6
8
9
Interest
8
17
16
15
12
12
11
19
22
24
19
23
23
Depreciation
5
19
19
20
19
22
22
32
32
32
34
40
40
PBT
40
56
42
60
62
51
91
68
5
66
92
117
119
Tax %
36%
26%
14%
33%
34%
36%
33%
1%
28%
26%
27%
25%
—
Net Profit
25
41
28
32
40
32
63
62
-7
50
69
102
102
EPS in Rs
2.55
4.83
3.36
3.75
4.73
3.73
7.38
7.35
-0.83
5.88
7.8
10.89
10.93
Div. Payout %
8%
4%
6%
7%
5%
7%
4%
4%
-36%
7%
5%
4%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
10
8
8
8
8
8
8
8
8
8
9
9
Reserves
182
285
246
276
313
340
402
462
452
528
631
776
Borrowings
73
204
149
146
144
157
255
263
254
281
311
365
Other Liabilities
64
158
89
72
93
103
147
126
165
217
202
212
Total Liabilities
329
656
493
503
559
608
812
860
880
1,034
1,153
1,362
Fixed Assets
69
370
290
279
281
280
457
438
412
437
533
534
CWIP
15
13
8
8
18
42
7
11
33
30
35
122
Investments
0
21
29
28
27
26
27
22
11
11
12
26
Other Assets
245
252
166
187
232
259
321
389
424
556
573
681
Total Assets
329
656
493
503
559
608
812
860
880
1,034
1,153
1,362
Figures in ₹ Crores

Cash Flow

Particulars Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
14
61
73
32
50
40
90
45
22
50
82
59
Investing
-32
-97
-39
-17
-35
-43
-152
-27
-30
-52
-123
-131
Financing
107
27
-33
-15
-13
-2
92
-12
-32
31
47
76
Net Cash Flow
89
-9
1
0
2
-5
31
6
-39
29
5
4
Free Cash Flow
-5
-27
50
23
15
-3
-61
18
-7
-2
-42
-71
CFO/OP
42
93
110
46
70
65
88
52
50
56
73
49
Figures in ₹ Crores

Ratios

Particulars Mar 2007Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
114
36
18
19
20
43
68
34
104
122
95
89
Inventory Days
165
106
114
135
170
191
148
333
243
201
238
260
Days Payable
72
79
82
49
59
66
70
97
117
130
95
89
Cash Conversion Cycle
206
63
50
105
131
169
146
270
230
192
237
260
Working Capital Days
169
19
-2
27
39
57
48
94
104
85
88
98
ROCE %
—
—
13%
18%
17%
13%
17%
13%
4%
12%
13%
13%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view SMS Pharmaceuticals insights

66 extracted metrics + investor summaries across FY07–FY27.

Log in — free

Shareholding Pattern

FIIs0.65%Promot.68.07%DIIs2.83%Others4.41%Public24.04%As ofJun 2026
17.99% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about SMS Pharmaceuticals

What does SMS Pharmaceuticals Ltd do?
SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]
Where is SMS Pharmaceuticals Ltd (SMSPHARMA) listed?
SMS Pharmaceuticals Ltd trades as SMSPHARMA on the NSE and under code 532815 on the BSE.
Which sector does SMS Pharmaceuticals Ltd belong to?
SMS Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd has a market capitalisation of ₹4,145 Cr, which places it in the Small Cap band.
What is the PE ratio of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd trades at a PE ratio of 42.40, on earnings per share of ₹6.73, against a book value of ₹83.91 per share.
What is the 52-week high and low of SMS Pharmaceuticals Ltd?
Over the last 52 weeks SMS Pharmaceuticals Ltd has traded between ₹242.25 and ₹447.8.
Does SMS Pharmaceuticals Ltd pay dividends?
SMS Pharmaceuticals Ltd has a dividend yield of 0.10%.
What is the Return on Equity (ROE) of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd reported a return on equity of 10.54%. Its debt-to-equity ratio is 0.46.

Company Information

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

Website smspharma.com
CEO Mr. Ramesh Babu Potluri
Employees 1,470
Listed 2007-02-28
Face Value ₹ 1
Issued Size 9,36,52,030

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SMSPHARMA.md for SMS Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List